Iloperidone for Schizophrenia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a long-acting injection of iloperidone can prevent worsening symptoms in people with schizophrenia. Participants will begin with iloperidone tablets and then switch to injections, with some receiving a placebo (inactive substance) for comparison. The trial seeks individuals diagnosed with schizophrenia who require ongoing psychiatric treatment. As a Phase 3 trial, this treatment is in the final step before FDA approval, offering participants an opportunity to contribute to a potentially groundbreaking therapy.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that iloperidone is generally safe and effective for treating schizophrenia. Studies found it to be as effective as haloperidol in preventing relapses over time.
Reported side effects are usually mild to moderate and include dizziness, dry mouth, and sleepiness. However, there is a more serious risk of heart problems, making regular check-ups important. Additionally, there is a warning about a higher risk of death in older adults with dementia-related psychosis.
Overall, many patients have safely used iloperidone, but discussing any concerns with a healthcare provider is important.12345Why do researchers think this study treatment might be promising?
Researchers are excited about iloperidone for schizophrenia because it offers a unique delivery method. Unlike the oral medications that are commonly used, iloperidone is available as a long-acting intramuscular injection. This could mean fewer doses and potentially improved adherence for patients. Additionally, iloperidone has a distinct mechanism of action, targeting specific receptors in the brain to help manage symptoms, which might offer benefits over existing antipsychotic options like risperidone and olanzapine.
What evidence suggests that iloperidone might be an effective treatment for schizophrenia?
Research has shown that iloperidone can help manage symptoms of schizophrenia. One study found that a daily dose of 12 mg significantly improved scores on a test measuring psychiatric symptoms compared to a placebo. Another study demonstrated that iloperidone improved overall schizophrenia symptoms based on a scale assessing symptom severity. Additionally, doses between 10-24 mg proved similarly effective, offering flexibility in dosing. These studies support the idea that iloperidone can be a useful treatment for schizophrenia. In this trial, participants will initially receive iloperidone during a 12-week stabilization phase, followed by randomization to receive either iloperidone long-acting injection or a matching placebo for up to 52 weeks.26789
Are You a Good Fit for This Trial?
This trial is for individuals who have been diagnosed with schizophrenia according to DSM-5 criteria and require continuous psychiatric treatment. Specific details on exclusion criteria are not provided, but typically these would include factors that could interfere with the study or patient safety.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Stabilization
Participants receive open-label iloperidone administered as oral tablets
Relapse Prevention
Participants receive open-label iloperidone as long-acting intramuscular injections
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Iloperidone
Trial Overview
The study is testing iloperidone in two forms: as a long-acting injection (LAI) and in oral form. The goal is to compare how the body handles both methods of delivering this medication in patients with schizophrenia.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
During the 12-week stabilization phase, all patients will receive open-label iloperidone administered as oral tablets (weeks 1-6) and as long-acting intramuscular injections (weeks 7-12). Subsequently, patients will be randomized in a 1:1 ratio to one of two arms: iloperidone long-acting injection or matching placebo. Post-randomization this arm will receive double-blind study drug (iloperidone long-acting injection) as long-acting intramuscular injections for up to 52 weeks.
During the 12-week stabilization phase, all patients will receive open-label iloperidone administered as oral tablets (weeks 1-6) and as long-acting intramuscular injections (weeks 7-12). Subsequently, patients will be randomized in a 1:1 ratio to one of two arms: iloperidone long-acting injection or matching placebo. Post-randomization this arm will receive double-blind study drug (matching placebo) as long-acting intramuscular injections for up to 52 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanda Pharmaceuticals
Lead Sponsor
Citations
Iloperidone (Fanapt): An FDA-Approved Treatment Option for ...
In study 1, iloperidone 12 mg/day was significantly more effective than placebo in improving BPRS scores. In study 2:
Atypical Antipsychotic Efficacy
Fanapt significantly improved overall schizophrenia symptoms as measured by PANSS 1,2 Improvement in symptoms in a 4-week study 2
Assessing the Effects of Fanapt® on Social Cognition ...
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently ...
Efficacy and Safety of Iloperidone in Bipolar Mania
At 4 weeks of treatment, patients receiving iloperidone showed significant improvement on the Young Mania Rating Scale versus those ...
Efficacy of iloperidone in schizophrenia: A PANSS five ...
Iloperidone demonstrated positive treatment effects on these newly derived PANSS factors. The 10–16 mg and 20–24 mg dose groups had similar efficacy on the ...
FANAPT (iloperidone) tablets - accessdata.fda.gov
Data from a placebo-controlled, 4-week, fixed-dose study, in which fasting blood samples were drawn, in adult subjects with schizophrenia are presented in Table ...
Prescribing Information
Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions in patients with schizophrenia that ...
Iloperidone (oral route) - Side effects & dosage
Iloperidone is used to treat schizophrenia. It is also used to treat manic ... Safety and efficacy have not been established. Geriatric. Appropriate ...
Iloperidone: uses, dosing, warnings, adverse events, ...
The prescribing information for iloperidone contains a boxed warning about the risk of increased mortality in geriatric patients with dementia-related psychosis ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.